Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
All news
Biotechnology
A new partnership between Porto, Portugal-based FairJourney Biologics and Cambridge, UK-based Iontas will look for effective antibodies for COVID-19. 17 April 2020
Biotechnology
Antibody specialist SAB Biotherapeutics has announced it has been awarded “expanded scope” by the US authorities in its program to develop a therapeutic for COVID-19. 17 April 2020
Biotechnology
Moderna saw its shares close up 9% yesterday and up more than 17% at $47.64 in pre-market trading today, after revealing a financing deal for its COVID-19 vaccine candidate. 17 April 2020
Biotechnology
The US regulator has granted Priority Review to a submission from Regeneron Pharmaceuticals to offer REGN-EB3 for Ebola. 16 April 2020
Biotechnology
US rare disease specialist Soligenix saw its shares rocket 89% pre-market, after it revealed it has executed an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp (NYSE: BSX), for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu. 16 April 2020
Biotechnology
Shares of Belgium’s Galapagos and Poland-based Ryvu Therapeutics both saw their shares rise this morning on news of a collaboration on the discover and development of small-molecule drugs in inflammation. 16 April 2020
Biotechnology
Swiss drugmaker Novartis has published new data supporting the long-term safety and efficacy of its CGRP blocker Aimovig (erenumab). 16 April 2020
Biotechnology
Canadian clinical-stage biotech Bold Therapeutics says it has initiated a research partnership with researchers from the University of Ottawa to explore the potential utility of BOLD-100, under development as an anti-cancer drug, as a novel antiviral agent. 15 April 2020
Biotechnology
Two new cancer companies, PIC Therapeutics and Amphista Therapeutics, have been launched by Advent Life Sciences. 15 April 2020
Biotechnology
European vaccine majors GlaxoSmithKline and Sanofi have signed a letter of intent to work together on an adjuvanted vaccine for COVID-19. 15 April 2020
Biotechnology
French companies LFB, formerly known as Laboratoire Francais du Fractionnement et des Biotechnologies, and biotech Xenothera have signed an agreement for the production by LFB of the first clinical batch of a drug candidate, XAV-19, developed by Xenothera for the treatment of coronavirus infections including COVID-19. 15 April 2020
Biotechnology
Sino-America biotech firm BeiGene’s were up 4.8% at HK$6,160 by close of trading yesterday, after it announced positive new trial results with its lung cancer candidate tislelizumab. 15 April 2020
Biotechnology
Daiichi Sankyo has commenced an open innovation research program relating to a gene therapy for restoring vision with Mitsubishi UFJ Capital and the Nagoya Institute of Technology (NITech). 14 April 2020
Biotechnology
The USA’s Blackstone revealed today that it will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases. 14 April 2020
Biotechnology
USA-based Eli Lilly has joined a large and rapidly growing list of drugmakers working on therapies to combat COVID-19, with the inclusion of Olumiant (baricitinib) in a National Institutes of Health (NIH)-backed trial. 14 April 2020
Biotechnology
Kolon Life Science has announced that the clinical hold issued by the US Food and Drug Administration in April 2019 has been lifted effective April 10, 2020, and that the company can continue with its knee osteoarthritis (OA) Phase III clinical trial of Invossa (TG-C). 14 April 2020
Biotechnology
Shares of US biotech firm Orgenesis were down more than 6% at $4.22 in early trading yesterday, after it announced an agreement to acquire the assets of Tamir Biotechnology (TamirBio), including ranpirnase, the latter’s broad spectrum anti-viral platform. 14 April 2020
Biotechnology
Gilead Sciences has announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with the investigational antiviral remdesivir on an individual compassionate use basis. 13 April 2020
Biotechnology
The ADAURA Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with complete tumor resection will be unblinded early following a recommendation from an Independent Data Monitoring Committee (IDMC) based on its determination of overwhelming efficacy. 12 April 2020
Biotechnology
The Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Braftovi (encorafenib) from Array BioPharma, which was acquired last July by Pfizer in an $11.4 billion deal. 10 April 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze